Nektar Therapeutics (NKTR)

Market Cap	2.13B +1,242.1%
Revenue (ttm)	55.23M -43.9%
Net Income	-164.08M
EPS	-9.73
Shares Out	28.69M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	699,972
Open	73.00
Previous Close	72.22
Day's Range	71.94 - 74.48
52-Week Range	6.48 - 77.00
Beta	1.23
Analysts	Strong Buy
Price Target	142.00 (+91.01%)
Earnings Date	Mar 12, 2026

About NKTR

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has col...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 3, 1994
• Employees: 61
• Stock Exchange: NASDAQ
• Ticker Symbol: NKTR
• Website: https://www.nektar.com

Financial Performance

In 2025, Nektar Therapeutics's revenue was $55.23 million, a decrease of -43.89% compared to the previous year's $98.43 million. Losses were -$164.08 million, 37.9% more than in 2024.

Analyst Summary

According to 6 analysts, the average rating for NKTR stock is "Strong Buy." The 12-month stock price target is $142.0, which is an increase of 91.01% from the latest price.

Price Target

$142.0

(91.01% upside)

Analyst Consensus: Strong Buy